Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients
by
Bremner JD, Abrahams LM, Crupie JE,
McCawley A, Proctor RC, Sathananthan GL
J Clin Psychiatry 1984 Apr; 45(4 Pt 2):56-9


ABSTRACT

Nomifensine, a tetrahydroisoquinoline antidepressant, was compared with imipramine in a 4-week multicenter double-blind study of depressed outpatients (100 on nomifensine, 56 on imipramine). Nomifensine was at least as effective as imipramine in reducing depressive symptoms at average doses of 150 mg/day. When significant differences did occur on Hamilton Depression Rating Scale scores, they favored nomifensine for improvement in cognitive symptoms and interest in work and activities. Early in treatment, nomifensine patients also showed a better relationship between clinical response and side effects. The proportions of patients experiencing at least one side effect or dropping out due to side effects were almost twice as high in the imipramine group. Dry mouth and sedating effects were 2-3 times more frequent among imipramine patients. Thus, nomifensine demonstrated clinical efficacy at least comparable with imipramine but with indications of a more favorable side effects profile.
TCAs
Amineptine
Comparative study
Nomifensine: profile
Retarded depression
Antidepressant toxicity
Nomifensine dependence
Noradrenaline and dopamine
Imipramine versus amineptine
Imipramine versus nomifensine
Nomifensine : pharmacokinetics
Nomifensine and hemolytic anemia
Nomifensine, noradrenaline and dopamine



Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family